Lupus

• 1. Introduction

  ›

  Lupus, formally called systemic lupus erythematosus or SLE, takes its name from the Latin word for wolf. The disease was named in the 13th century, when its rash was thought to resemble a wolf's bite. Yet the real story lies beneath the skin. In lupus, the immune system mistakes healthy tissue for a threat and attacks it, often in many parts of the body at once.

  Symptoms range from mild to severe. They arrive in periods of illness called flares and then fade into periods of remission, when few symptoms remain. This documentary follows the questions the disease raises. Why does a defense system turn on the body it protects? Why do some people wait years for an answer? How do doctors find lupus today, and what has treatment changed about life with it?

  26881100

• 2. The Great Imitator

  ›

  Fever, malaise, joint pain, muscle pain and fatigue are the common first complaints of lupus. They are also the reason the disease carries the nickname "the great imitator." The same list appears in many other illnesses, so these complaints are not part of the formal diagnostic criteria. Combined with other signs, however, they are considered suggestive.

  Symptoms of lupus come and go unpredictably. Some people live with unexplained symptoms for years before a definitive diagnosis is reached. Doctors treat SLE as a classic item in differential diagnosis, the list of possible explanations they work through for a puzzling set of symptoms.

  Women are affected far more often than men, and the illness looks different in each sex. Females tend to have more relapses, lower white blood cell counts, more arthritis, Raynaud syndrome and psychiatric symptoms. Males tend to have more seizures, kidney disease, skin problems and peripheral neuropathy.

  As many as 70 percent of people with lupus have some skin symptoms. Doctors sort the lesions into three groups. Chronic cutaneous, or discoid, lupus produces thick, red, scaly patches. Subacute cutaneous lupus produces scaly patches with distinct edges. Acute cutaneous lupus appears as a rash, and its classic form is the malar rash, known as the butterfly rash, seen in 30-60 percent of people with SLE. Hair loss and mouth and nasal ulcers are also possible.

  More than 90 percent of people with lupus will have joint or muscle pain at some point. The small joints of the hand and wrist are usually affected, though any joint is at risk. Lupus arthritis is less disabling than rheumatoid arthritis, and fewer than ten percent of those with it develop deformities of the hands and feet.

  Anemia develops in about 50 percent of children with SLE. Low platelet counts and low white blood cell counts may come from the disease or from its treatment. One antibody found in SLE, the anti-cardiolipin antibody, can even cause a false positive test for syphilis. That strange side effect hints at how far the disease reaches into the blood, and the organs that depend on it.

  127151626

• 3. Heart, Kidneys, Brain

  ›

  Inflammation from lupus can strike the heart in three places: the outer lining, the muscle itself and the inner lining. The inner-lining form is not caused by infection. It is called Libman-Sacks endocarditis and involves either the mitral valve or the tricuspid valve. Atherosclerosis also occurs more often in people with lupus than in the general population, and it advances more rapidly. The lungs can be affected too, through pleurisy, which can rarely lead to shrinking lung syndrome and a reduced lung volume.

  Painless passage of blood or protein in the urine may be the only sign that the kidneys are involved. Lupus nephritis can lead to acute or end-stage kidney failure. Because of early recognition and treatment with immunosuppressive drugs or corticosteroids, end-stage renal failure occurs in less than 5 percent of cases. The exception is the black population, where the risk is many times higher.

  The American College of Rheumatology defines 19 neuropsychiatric syndromes in lupus. Diagnosing them is described as one of the most difficult challenges in medicine. The patterns of symptoms are so varied that some are mistaken for infectious disease or stroke. Headache is common, though whether a specific lupus headache exists remains controversial. Other manifestations include cognitive disorder, mood disorder, seizures, anxiety and psychosis. Depression affects up to 60 percent of women with SLE in certain regions. Steroid psychosis can also occur as a result of treating the disease.

  Up to one-third of patients report that their eyes are affected. The most common problems are dry eye syndrome and secondary Sjögren's disease. Scleritis, retinopathy, retinal detachment and secondary angle-closure glaucoma may also occur. The treatments carry their own eye risks. Long-term glucocorticoid use can cause cataracts and secondary open-angle glaucoma, and long-term hydroxychloroquine treatment can cause vortex keratopathy and maculopathy.

  2736454832

• 4. Why the Body Turns

  ›

  Among identical twins, if one has lupus there is a 24 percent chance that the other will develop it too. That number shows that genes matter but do not decide everything. Female sex hormones, sunlight, smoking, vitamin D deficiency and certain infections are also believed to raise a person's risk. The exact cause remains unclear.

  Childhood-onset lupus, which develops before the age of 18, sometimes has a single-gene cause. Mutations in about 40 genes have been reported to cause it or a similar disorder. This form is typically more severe and potentially lethal than adult-onset disease, because it often involves neurologic disease, kidney failure or macrophage activation syndrome. Some of the genes code for complement component 4, a protein that helps regulate immune function. Its two parts come from the genes C4A and C4B, and people who make too little of the protein are at risk.

  Mutations in a wide range of other genes do not cause the disease alone. Two or more may act together, combine with environmental factors, or act only in certain populations. Some, for example, cause SLE in Chinese people but not in Europeans. People with SLE also show higher levels of DNA damage than normal subjects, and defective DNA repair is a likely mechanism.

  A drug-induced form of lupus mimics SLE but is generally reversible, with symptoms fading once the triggering medication is stopped. A drug safety database recorded 12,166 cases of drug-induced SLE between 1968 and 2017, linked to 118 different agents. Five main classes were most often involved. They included heart-rhythm drugs, blood-pressure drugs, antimicrobials and agents that block inflammatory signals from interferon or tumor necrosis factor.

  A Stanford University study published in November 2025 suggests how the Epstein-Barr virus could lead to SLE. The infection reprograms B cells that react against the cell nucleus, driving them toward autoimmunity. Vitamin D is murkier. Some studies found low levels in people with SLE and others did not, and results varied between populations.

  Whatever starts the process, the immediate cause is a set of antibodies aimed at the body's own proteins, particularly those in the cell nucleus. One leading explanation focuses on how the body clears away dying cells. Early in orderly cell death, cells display "eat-me" signals such as phosphatidylserine and send out find-me signals that attract macrophages and dendritic cells.

  In lupus, that cleanup falters. Tingible body macrophages, large scavenger cells in the germinal centers of lymph nodes, are scarce in some people with SLE and rarely contain material from dead B cells. Nuclear debris builds up and attaches to follicular dendritic cells. There it acts as a survival signal for autoreactive B cells that would normally die. With help from autoreactive T cells, they mature into plasma cells that make autoantibodies.

  Researchers have also found that some people with lupus nephritis cannot properly break down neutrophil extracellular traps. Chemical messengers including BAFF, also called B-lymphocyte stimulator, drive the resulting inflammation. They are now potential therapeutic targets.

  1063787992

• 5. Finding Lupus

  ›

  Antinuclear antibody testing, known as ANA, is the mainstay of blood testing for lupus. The test is highly sensitive, and the vast majority of people with lupus test positive. It is not specific, because positive results also appear in other connective tissue disorders and sometimes in normal individuals.

  A subtype called the anti-double-stranded DNA antibody is far more telling. It is present in 70 percent of lupus cases but in only 0.5 percent of people without SLE. Its levels also tend to reflect disease activity, though not in every case. Anti-histone antibodies, by contrast, point toward drug-induced lupus. Doctors also check complement levels, kidney function, electrolytes, liver enzymes and a complete blood count.

  The lupus erythematosus cell test, once commonly used, is now performed only rarely. LE cells turn up in only 50-75 percent of SLE cases. They also appear in rheumatoid arthritis, scleroderma and drug sensitivities.

  A newer multianalyte panel combines several autoantibody tests with a measurement of cell-bound complement activation products. It showed 80 percent diagnostic sensitivity and 86 percent specificity in telling SLE apart from other autoimmune connective tissue diseases. In a study of over 40,000 patients, those who tested positive on the panel had up to six times the odds of receiving a new SLE diagnosis, compared with patients testing positive by traditional ANA testing.

  In 1982 the American College of Rheumatology established eleven criteria, and revised them in 1997. They were built to define lupus in clinical trials, not to diagnose individuals, and they do poorly at that job. For research, a person has SLE if any 4 of the 11 are present together or over time. Each criterion has its own track record. A positive ANA test has 99 percent sensitivity but only 49 percent specificity. Discoid rash is found in just 18 percent of cases, yet it is 99 percent specific.

  Recursive partitioning, a statistical method, produced simpler rules for individual diagnosis. The simplest classification tree diagnoses SLE when a person has an immunologic disorder or a malar rash, and has sensitivity and specificity of 92 percent each. A fuller tree using six criteria reaches 97 percent sensitivity and 95 percent specificity.

  10081189855

• 6. Treatment and Outlook

  ›

  Hydroxychloroquine was approved by the FDA for lupus in 1955, and it remains a first-line drug. It is associated with a 54 percent reduction in mortality from SLE. All people with SLE are advised to take it unless allergy or significant retinal disease rules it out. The risk to the eyes is rare, with retinal toxicity affecting 2 percent of long-term users at 10 years, so regular eye exams are recommended.

  There is no cure for lupus. Treatment aims to prevent flares and to reduce their severity and duration. Corticosteroids work rapidly, but long-term use brings side effects. Depending on the dose, people who need steroids may develop Cushing's syndrome, with a puffy round face, diabetes, increased appetite, poor sleep and osteoporosis. Even low doses over the long term can cause high blood pressure and cataracts. Cyclophosphamide is reserved for severe kidney disease or other organ damage, and it raises the risk of infections.

  In November 2010, an FDA advisory panel recommended approving belimumab, sold as Benlysta, for the pain and flare-ups common in lupus. The FDA approved it in March 2011. The drug is a fully human monoclonal antibody that targets BAFF, and it was tested in a study called BLISS-76.

  Sunlight is a major concern, because ultraviolet radiation is known to worsen the skin disease. Fatigue can be debilitating, and the two problems together can leave people housebound for long periods. Physical exercise has been shown to improve fatigue in adults with SLE.

  Most pregnancies in women with lupus are successful, and the overall live-birth rate is estimated at 72 percent. The risks of miscarriage, preterm birth and neonatal lupus are higher, though neonatal lupus is rare and usually benign. Women known to carry anti-Ro or anti-La antibodies often have echocardiograms during the 16th and 30th weeks of pregnancy to monitor heart health.

  In the 1950s, most people diagnosed with SLE lived fewer than five years. Today over 90 percent survive for more than ten years, and 80-90 percent can expect a normal lifespan. Cardiovascular disease, driven by accelerated atherosclerosis, is the leading cause of death.

  In September 2022, researchers at the University of Erlangen-Nuremberg published results from five severely ill patients, four women and one man. Each received transfusions of CAR T cells, genetically altered to attack their B cells. The therapy drove the disease into remission in all five, and they stayed disease-free off lupus medication for several months after the treatment ended.

  62949534

• 7. Who Gets Lupus

  ›

  Worldwide, SLE affects roughly 20 to 70 people per 100,000. The rate is lowest in Iceland and Japan and highest in the United States and France. One US estimate is 53 per 100,000, while Northern Europe sits around 40. Among people of Afro-Caribbean descent the rate has been found to be as high as 159 per 100,000. Nobody has shown why the rate differs between countries, though differences in sunlight and ultraviolet exposure are one possibility.

  Women are affected at a rate of about 9 to 1 compared with men. Hormones may explain part of that gap, including elevated hydroxylation of estrogen and abnormally low androgen levels in females. The X chromosome may matter as well. It carries immune genes such as CD40L, which can mutate or escape the silencing that normally switches off one X chromosome in females. A study has also linked Klinefelter syndrome, in which males carry an extra X chromosome, to SLE.

  Childhood-onset lupus generally appears between the ages of 3 and 15 and is four times more common in girls. In the United States, the recorded rate of SLE rose from 1.0 in 1955 to 7.6 in 1974. Whether that reflects better diagnosis or a genuine increase is unknown.

  A 2010 review of studies linking race and SLE found several sources of systematic and methodological error, suggesting the connection may be spurious. Social support buffers against lupus damage, yet studies have not tested whether support differs between racial groups. Studies that control for socioeconomic status find no racial differences in lupus progression. Differences in late-stage outcomes most likely reflect differences in access to care. Women with SLE and lower socioeconomic status have higher depression scores, higher body mass index and more restricted access to medical care.

  Such numbers only exist because physicians first learned to recognize the disease, and that took centuries.

  93515713

• 8. Naming the Wolf

  ›

  Rogerius Frugard, an Italian physician of the 12th century, is credited with using the word lupus in a sense close to its modern one. He applied it to ulcerating sores on the legs. The second half of the name comes from the Ancient Greek erythema, meaning redness of the skin. Other ulcerating diseases borrowed the same Latin word, including lupus vulgaris, a facial tuberculosis unrelated to lupus erythematosus.

  In 1851, the French physician Pierre Cazenave documented the skin disease now called discoid lupus. He added the word erythematosus to separate it from skin illnesses that were infectious. He recorded detailed notes on several patients and was among the first to note that a facial rash is the disease's most distinguishing feature.

  Ferdinand von Hebra and his son-in-law Moritz Kaposi carried the work forward. Hebra saw that symptoms could last many years, go dormant after aggressive activity and then return in the same pattern. In 1872 he termed lupus a chronic disease. Kaposi described a more severe form that brought fever and arthritis, and he coined the name "butterfly rash."

  Sir William Osler published the first of three papers on internal complications in 1895. Because many patients had illness beyond the skin, he added the word "systemic." His third paper, published in 1903, recorded arthritis, pneumonia, delirium and central nervous system damage.

  Quinine was reported as an effective therapy in 1894. Four years later, salicylates used together with quinine were found to help more. This remained the best treatment until the middle of the twentieth century, when Hench discovered that corticosteroids worked.

  In 1948, a team at the Mayo Clinic discovered the LE cell, a white blood cell containing the nucleus of another cell. The finding led to an easier test for antinuclear antibodies and to the modern understanding of autoimmune disease.

  Medical historians have also theorized that folklore about vampires and werewolves arose from porphyria, a disease that shares many symptoms with SLE.

  In Thailand, the singer Pumpuang Duangjan died of lupus, and many Thai people know the disease as Phumpuang disease. The novelist Flannery O'Connor and the singers Michael Jackson, Toni Braxton, Seal and Selena Gomez appear among the famous names linked to it.

  81855212